Precigen/$PGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Precigen
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Ticker
$PGEN
Sector
Primary listing
Employees
143
Headquarters
Website
Precigen Metrics
BasicAdvanced
$1.2B
-
-$0.43
1.87
-
Price and volume
Market cap
$1.2B
Beta
1.87
52-week high
$5.23
52-week low
$0.65
Average daily volume
5.5M
Financial strength
Current ratio
2.706
Quick ratio
2.601
Long term debt to equity
-71.625
Total debt to equity
-87.398
Interest coverage (TTM)
-31,484.00%
Profitability
EBITDA (TTM)
-91.858
Gross margin (TTM)
-1,213.53%
Net profit margin (TTM)
-2,868.66%
Operating margin (TTM)
-2,176.31%
Effective tax rate (TTM)
0.06%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-67.44%
Return on equity (TTM)
-668.03%
Valuation
Price to revenue (TTM)
271.209
Price to book
-32.88
Price to tangible book (TTM)
-21.66
Price to free cash flow (TTM)
-16.869
Free cash flow yield (TTM)
-5.93%
Free cash flow per share (TTM)
-0.241
Growth
Revenue change (TTM)
-1.12%
Earnings per share change (TTM)
-20.77%
3-year revenue growth (CAGR)
-34.50%
10-year revenue growth (CAGR)
-28.88%
3-year earnings per share growth (CAGR)
-2.21%
10-year earnings per share growth (CAGR)
-0.61%
What the Analysts think about Precigen
Analyst ratings (Buy, Hold, Sell) for Precigen stock.
Bulls say / Bears say
On August 15, 2025, the U.S. FDA approved Precigen’s immunotherapy PAPZIMEOS for adults with recurrent respiratory papillomatosis, making it the first FDA-approved treatment for this rare disease and pushing shares up 81% premarket (Reuters).
As of March 31, 2025, Precigen held $81.0 million in cash, cash equivalents, and investments, enough to fund operations into 2026 and support its 2025 commercial launch plans (PRNewswire).
On September 3, 2025, Precigen secured a $125 million non-dilutive credit facility from Pharmakon Advisors, strengthening its financial position to support U.S. commercialization and global expansion of PAPZIMEOS (RTTNews).
Precigen’s first quarter 2025 net loss grew to $54.2 million (−$0.18 per share), mainly due to a $32.5 million non-cash increase in warrant liabilities, signaling continued profitability issues (PRNewswire).
On September 18, 2025, Director Randal J. Kirk sold 1,403,360 shares at an average price of $3.86, reducing his holding by more than 10%—potentially indicating insider doubts about Precigen’s near-term prospects (MarketBeat).
On May 15, 2025, HC Wainwright lowered its full-year 2025 EPS forecast for Precigen to ($0.37) from ($0.29), highlighting increased concerns about profitability as PAPZIMEOS approaches commercialization (Defense World).
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
Precigen Financial Performance
Revenues and expenses
Precigen Earnings Performance
Company profitability
Precigen News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Precigen stock?
Precigen (PGEN) has a market cap of $1.2B as of October 29, 2025.
What is the P/E ratio for Precigen stock?
The price to earnings (P/E) ratio for Precigen (PGEN) stock is 0 as of October 29, 2025.
Does Precigen stock pay dividends?
No, Precigen (PGEN) stock does not pay dividends to its shareholders as of October 29, 2025.
When is the next Precigen dividend payment date?
Precigen (PGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Precigen?
Precigen (PGEN) has a beta rating of 1.87. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.